Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase, investigated in five randomized Phase 2 trials. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 670 patients at 100 clinics in 15 countries, in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. The results from the first randomized Phase II trial in malignant mesothelioma showed a significant and clinically meaningful improvement in patients receiving UV1 cancer vaccine as add-on to ipilimumab and nivolumab. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is publicly listed at Euronext Oslo (ULTI). Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and has an office in Uppsala, Sweden.
